Comment
doi: 10.1038/s41571-019-0234-0.
Alpelisib effective in advanced-stage disease
Affiliations
- PMID: 31127192
- DOI: 10.1038/s41571-019-0234-0
Item in Clipboard
Comment
Alpelisib effective in advanced-stage disease
Nat Rev Clin Oncol.
2019 Aug.
No abstract available
Comment on
-
Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer.N Engl J Med. 2019 May 16;380(20):1929-1940. doi: 10.1056/NEJMoa1813904. N Engl J Med. 2019. PMID: 31091374 Clinical Trial.
Similar articles
-
Alpelisib for PIK3CA-Mutated Advanced Breast Cancer.N Engl J Med. 2019 Aug 15;381(7):686-687. doi: 10.1056/NEJMc1907856. N Engl J Med. 2019. PMID: 31412192 No abstract available.
-
Alpelisib for PIK3CA-Mutated Advanced Breast Cancer.N Engl J Med. 2019 Aug 15;381(7):686. doi: 10.1056/NEJMc1907856. N Engl J Med. 2019. PMID: 31412191 No abstract available.
-
Alpelisib for PIK3CA-Mutated Advanced Breast Cancer. Reply.N Engl J Med. 2019 Aug 15;381(7):687. doi: 10.1056/NEJMc1907856. N Engl J Med. 2019. PMID: 31412193 No abstract available.
-
Alpelisib to treat breast cancer.Drugs Today (Barc). 2020 Jun;56(6):357-363. doi: 10.1358/dot.2020.56.6.3137526. Drugs Today (Barc). 2020. PMID: 32525134 Review.
-
A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.Expert Opin Drug Metab Toxicol. 2021 Feb;17(2):139-152. doi: 10.1080/17425255.2021.1844662. Epub 2020 Dec 8. Expert Opin Drug Metab Toxicol. 2021. PMID: 33213227 Review.
Cited by
-
Combined Treatment with PI3K Inhibitors BYL-719 and CAL-101 Is a Promising Antiproliferative Strategy in Human Rhabdomyosarcoma Cells.Molecules. 2022 Apr 24;27(9):2742. doi: 10.3390/molecules27092742. Molecules. 2022. PMID: 35566091 Free PMC article.
-
Structural Basis for Vascular Endothelial Growth Factor Receptor Activation and Implications for Disease Therapy.Biomolecules. 2020 Dec 15;10(12):1673. doi: 10.3390/biom10121673. Biomolecules. 2020. PMID: 33333800 Free PMC article. Review.
References
Original article
-
- André, F. et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N. Engl. J. Med. 380, 1929–1940 (2019) - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
